Mundipharma: Swissmedic reviewing licence extension for the SGLT2 inhibitor Invokana® (canagliflozin) in fast-track procedure
Mundipharma welcomes the news that Swissmedic (the Swiss Agency for Therapeutic Products; the surveillance authority for medicines and medical devices in Switzerland) is conducting a fast-track review of Mundipharma Switzerland’s application to extend marketing authorisation for the SGLT2 inhibitor canagliflozin as an adjunct to the standard of care in adults with type 2 diabetes mellitus (T2DM) and stage 2 or stage 3 chronic kidney disease (CKD) and albuminuria. The submission is based on data from the Phase III CREDENCE study, which evaluated the efficacy and safety of canagliflozin versus placebo in this high-risk patient population when used in addition to the current standard of care.1
“Chronic kidney disease is a serious complication of type 2 diabetes, which can increase patients’ risk of developing end-stage renal disease and may reduce their life expectancy by several years.” said Dr Vinicius Gomes de Lima, European Medical Affairs Lead, Mundipharma. “If approved, this licence extension in Switzerland would be the first significant step forward in nearly two decades, to help reduce the associated burden of chronic kidney disease and improve quality of life for these patients.”
Approximately 40% of T2DM patients develop diabetic kidney disease (DKD)2. This has a major impact on their physical and emotional health as well as their quality of life, and amplifies their risk of additional diabetes complications such as cardiovascular disease, infections, fatigue, depression, adverse drug reactions and premature death.3 Data from the Swiss dialysis registry show that around one third of dialysis patients have T2DM and that approximately 17% of patients have diabetic nephropathy as an underlying kidney disease.4 There is therefore a great need for new therapies that cater for the kidney-related complications of T2DM.2
Canagliflozin has been authorised in Switzerland since 2014 for the treatment of adults with insufficiently controlled T2DM as an adjunct to diet and exercise, either as monotherapy or in addition to other blood sugar-reducing medicinal products.5
In Europe, canagliflozin is currently indicated for the treatment of adults with insufficiently controlled T2DM as an adjunct to diet and exercise. The initiation dose is 100mg once daily in adults with an eGFR of ≥ 60 mL/min/1.73 m2 and can be increased to 300mg once daily orally if tighter glycaemic control is needed. Canagliflozin should not be initiated if eGFR is < 60 mL/min/1.73 m2. In patients tolerating canagliflozin whose eGFR falls persistently below 60 mL/min/1.73 m2 the dose should be adjusted to or maintained at 100mg once daily. Canagliflozin should be stopped if eGFR falls persistently below 45 mL/min/1.73 m2.6
Canagliflozin has been approved in the European Union since 2013 and was approved for use in Switzerland in 2014.
-END-
Notes to the editors:
About Invokana (canagliflozin)®6
Canagliflozin is an oral, once-daily medication that belongs to a class of medications called sodium glucose co-transporter 2 (SGLT2) inhibitors. SGLT2 inhibitors work by inhibiting SGLT2 co-transporter, which promotes the excretion of glucose via the urine, and thus helps lowering blood glucose levels in adults with T2DM.
Canagliflozin was approved in the European Union by the European Commission in November 2013. It is indicated for the treatment of adults with insufficiently controlled T2DM as an adjunct to diet and exercise, as monotherapy when metformin is considered inappropriate due to intolerance or contra-indications and in addition to other medicinal products for the treatment of diabetes. Approval was based on a comprehensive global Phase III clinical trial programme.
Swissmedic authorised canagliflozin for marketing in Switzerland in 2014, where it is indicated for the treatment of adults with insufficiently controlled T2DM as an adjunct to diet and exercise and in addition to other blood sugar-lowering medicinal products.
About the CREDENCE Clinical Trial
1
The CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) study was the first dedicated and fully recruited renal outcome trial evaluating renal and cardiovascular outcomes in people with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) with a sodium glucose co-transporter 2 (SGLT2) inhibitor. It was a phase III randomised, double-blind, event-driven, placebo-controlled, parallel-group, two-arm multicentre study of the effects of canagliflozin on renal and cardiovascular outcomes in subjects with T2DM and CKD. In particular, it compared the efficacy and safety of canagliflozin versus placebo in preventing clinically important kidney and cardiovascular outcomes in patients with T2DM and CKD when used in addition to standard of care, including a maximum tolerated daily dose of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB). The study was stopped early in July 2018 owing to positive efficacy findings.
About the Mundipharma network
Mundipharma is a global network of privately-owned independent associated companies whose purpose is to move medicine forward. With a high performing and learning organisation that strives for innovation and commercial excellence through partnerships, we successfully transformed and diversified our European portfolio of medicines to create value for patients, payers and wider healthcare systems across important therapeutic areas such as Diabetes, Respiratory, Oncology, Pain and Biosimilars.
Invokana® is a registered trademark of Janssen and its group companies.
References:
1 Perkovic, V., et al., Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. New England Journal of Medicine. 2019; 380(24): 2295-2306.
2 Alicic, R.Z., Rooney, M.T., Tuttle K.R. Diabetic Kidney Disease -Challenges, Progress, and Possibilities. Clin J Am Soc Nephrol 2017; 12: 2032–2045.
3 CDC. National Chronic Kidney Disease Fact Sheet, 2017. Available at: https://www.cdc.gov/kidneydisease/pdf/kidney_factsheet.pdf. Last accessed September 2019.
4 Ambühl, P.M. Das Schweizer Dialyseregister - Aktuelle Erkenntnisse zur Schweizer Dialysepopulation. Hausarzt Praxis 2017;. 12(3). Available at http://www.swissnephrology.ch/media/srrqap/MedizinAktuell_2017_aktuelle_Erkenntnisse.pdf. Last accessed September 2019.
5 Swissmedic. Invokana® Product information (Updated May 2019). Available at www.swissmedicinfo.ch. Last accessed September 2019
6 Invokana SmPC. Available at: https://www.ema.europa.eu/en/documents/product-information/invokana-epar-product-information_en.pdf Last accessed September 2019.
Job code: MBL/DIAB-19029
Date of preparation: October 2019
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191009005652/en/
Contact information
Athos Del Ponte
Head of Market Access, Regulatory and External Affairs
Phone: +41 205 11 63
E-mail: athos.del.ponte@mundipharma.ch
Cendrine Banerjee-Quetel
Asset Communications Associate, Mundipharma International Ltd
Email: Cendrine.Banerjee-Quetel.external@mundipharma.com
Tel: +44 1223 393 009
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Citi and Ant International Pilot AI-Enabled Forecasting Solution to Enhance FX Risk Management for Airline Customers18.7.2025 05:30:00 EEST | Press release
Citi and Ant International announced today that they are piloting the use of Ant International's Falcon Time-Series Transformer (TST) Model to deliver an enhanced FX risk management solution for their customers. Developed with aviation clients as an initial use case, the solution aims to offer greater payment solutions for the airline industry, which processes billions of payment transactions annually. With airline travel set to continue growing, the joint solution combines Ant International's experience with airline payments and Citi's robust FX solutions to help the bank's clients manage their FX costs more efficiently. Ant International’s Falcon TST Model is a transformer architecture-based big data model with close to 2 billion parameters. By integrating the latest time series forecasting algorithms, the TST Model predicts future data points by learning complex patterns from large historical data sets using AI technology, the model helps businesses improve the efficiency and accura
AGC Launches Innovative Fluoroelastomer Without the Use of Surfactants or Fluorinated Polymerization Solvents18.7.2025 05:00:00 EEST | Press release
AGC (AGC Inc., Headquarters: Tokyo; President: Yoshinori Hirai)(TOKYO:5201), a world-leading manufacturer of glass, chemicals and other high-tech materials, proudly announces the launch of surfactant and fluorinated polymerization solvent free grades in its fluoroelastomer “AFLAS™ FFKM” series; the SF grades (the “Products”). The newly developed Products are manufactured entirely without the use of any surfactants*1 or fluorinated polymerization solvents*2. The Products offer high performance equivalent to that of conventional products, while meeting the growing market demand for fluoroelastomers that do not use surfactants or fluorinated polymerization solvents during the manufacturing process. This has been achieved through AGC’s innovative, proprietary polymer manufacturing technology (Surfactant-Free & Fluoro Solvent-Free Technology, hereafter the “Technology”). Initially, this Technology will be applied to the high-temperature-resistant type of FFKM fluoroelastomers and new grades
Dubai Launches World’s First Icon Classification for Human–Machine Collaboration in Research and Publications17.7.2025 19:40:00 EEST | Press release
Dubai has launched the world’s first icon-based classification system to represent the level of human–machine collaboration in the process of producing research, publications, and public-facing content. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250717193317/en/ Dubai launches world’s first icon classification for Human–Machine Collaboration in research and publications (Infographic: AETOSWire) Developed by the Dubai Future Foundation (DFF), the Human–Machine Collaboration (HMC) Icons offer a new global standard for transparency, clearly indicating the extent to which humans and AI worked together throughout the creation process. The classification is free to use, copyrighted for consistency, and openly available for researchers, publishers, and content creators worldwide. His Highness Sheikh Hamdan bin Mohammed bin Rashid Al Maktoum, Crown Prince of Dubai, Deputy Prime Minister, Minister of Defence, and Chairman of the
Battery Ventures Promotes Justin Rosner to Partner17.7.2025 16:47:00 EEST | Press release
Battery Ventures, a global, technology-focused investment firm, today announced nearly a dozen new internal promotions across four offices, including the elevation of Justin Rosner—a specialist in industrial technology and life-science tools—to partner. Battery also named four new principals across its venture-capital and private-equity practices, highlighting the firm’s penchant for promoting talent from within the firm. The new principals are Sudheendra Chilappagari in San Francisco; Michael Hoeksema in New York; Lior Mallul in Tel Aviv; and Lauren Wedell in Boston. Wedell and Mallul both joined Battery in 2018, while Hoeksema joined in 2017. Chilappagari, a former founder and technology product executive, joined the firm in 2021. “These promotions highlight Battery’s continued, global investment focus, even in the face of macroeconomic uncertainty, and our commitment to backing the most innovative companies across the private-equity and venture-capital markets,” said Jesse Feldman,
Andersen Consulting Adds Market Access Expertise with Prime Action in Brazil17.7.2025 16:30:00 EEST | Press release
Andersen Consulting strengthens its capabilities in Latin America with the addition of collaborating firm Prime Action Consulting, a firm specializing in market access strategy and channel management within the automotive, agribusiness, banking, pharmaceutical, and telecommunications sectors. Prime Action delivers end-to-end commercial consulting services to help organizations optimize their go-to-market strategies and improve performance across sales and distribution channels. The firm’s offerings include market access strategy, intelligent channel management, commercial and distribution policy design, channel development services, and training, all tailored to drive efficiency and customer alignment through structured processes, standards, and targeted execution. Working with top-tier companies across Latin America, Prime Action not only works in lockstep with clients from planning through implementation, but also post-implementation to provide appropriate training and evaluation to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom